Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study.
Latest Information Update: 13 Dec 2023
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CURE
- 17 Oct 2023 Results evaluating the sustained deep remission rate one year after discontinuation of a 12-month course of adalimumab, presented at the 31st United European Gastroenterology Week
- 28 Mar 2019 Planned End Date changed from 1 Sep 2024 to 1 Mar 2025.
- 28 Mar 2019 Planned primary completion date changed from 1 Feb 2023 to 1 Mar 2021.